Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 3;21:48. doi: 10.1186/s12964-023-01065-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — ARID1A expression serves as a novel biomarker for resistance to first-generation EGFR-TKIs in EGFR-mutant lung adenocarcinoma patients. A Underlying mechanisms based on differentially expressed proteins revealed by mass spectrometry for phosphorylated proteins, which might be associated with resistance to EGFR-TKIs. B Representative images of IHC staining of ARID1A in EGFR-mutant lung adenocarcinoma. C Progression-free survival after treatment with first-generation EGFR-TKIs in all enrolled patients and patients who received gefitinib (divided by ARID1A expression). D ROC curve for ARID1A expression in predicting the progression-free survival of patients treated with first-generation EGFR-TKIs. E The construction and verification of a nomogram based on ARID1A expression and ECOG score for EGFR-mutant lung adenocarcinoma patients who received first-generation EGFR-TKIs. F Drug selection based on the NCI-60 database for non-small cell lung cancer patients with ARID1A deficiency